Cabozantinib Plus Atezolizumab Active in mCRPC

11:56 EST 11 Feb 2020 | OncLive

The combination of cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Original Article: Cabozantinib Plus Atezolizumab Active in mCRPC


More From BioPortfolio on "Cabozantinib Plus Atezolizumab Active in mCRPC"

Quick Search

Relevant Topic

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...